SuperworthLakewood-Amedex Biotherapeutics EPS LABT
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$2.75
Lakewood-Amedex Biotherapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$2.75.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$2.75 | n/a | |
| Q1 FY26 | −$2.00 | n/a | |
| Q2 FY25 | −$1.66 | n/a | |
| Q1 FY25 | −$1.50 | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Lakewood-Amedex Biotherapeutics' size, closest first, today.
| Company | EPS, 12 months |
|---|---|
| LABTLakewood-Amedex Biotherapeutics | n/m |
| NXTSNexentis Technologies | n/m |
| JAGXJaguar Health | −$6051.75 |
| VBIOValion Bio | n/m |
| DCOYDecoy Therapeutics | n/m |
| SBFMSunshine Biopharma | n/m |
| ARTLArtelo Biosciences | −$207.09 |
| LNAILunai Bioworks | n/m |
| GNPXGenprex | n/m |
| GOVXGeoVax Labs | n/m |
| ONCOOnconetix | −$199.38 |
| Peer median | −$207.09 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Lakewood-Amedex Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.